Clinical trials: HIV Infection Asymptomatic
- Condition HIV Infection Asymptomatic
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
HIV
A Phase 2 Study Of PF-00232798 In HIV Positive Patients
To assess the viral load response, safety, tolerability and pharmacokinetics of multiple oral doses of PF 00232798 in HIV-positive patient volunteers.
- Trial name
- NCT00495677
- Testing
- PF-00232798
- Where
- 2 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Pfizer
HIV-1
A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061
A phase 2a study to investigate the effects of 7-day monotherapy of UK-453,061 on viral load response in asymptomatic human immunodeficiency virus (HIV) infected subjects, to assess the dose-response relationship, and to assess…
- Trial name
- NCT00348673
- Testing
- UK-453,061
- Where
- 3 sites in Germany
- Volunteers
- 49 people
- Sponsor
- Pfizer
HIV Infections
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
This protocol represents the third in human study of TUTI-16, and is being conducted to gather additional safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
- Trial name
- NCT01335191
- Testing
- TUTI-16 (1.0 mg)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Thymon, LLC
HIV Infections
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
This protocol represents the first in human study of TUTI-16, and is being conducted to establish the safety and human immunogenicity (anti-HIV-1 Tat titers) of subcutaneously administered TUTI-16.
- Trial name
- THYMON-08001 (NCT00848211)
- Testing
- TUTI-16 (0.03mg), TUTI-16 (0.1mg), TUTI-16 (0.6mg)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Thymon, LLC